William Michael Kavanaugh, CSO, Head Res.&Non-Clin. Development at CytomX Therapeutics, Inc. (CTMX), bought 5,000 shares at $12.00 ($60K) on 2015-10-14, disclosed to the SEC on 2015-10-16.
Open-market purchase of $60k CTMX by CSO, Head Res.&Non-Clin. Development. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history).
Nothing distinguishes this filing.